Skip to content
Adrienne Monson – Lifestyle
Author:
BioNTech SE
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
September 14, 2026
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
August 27, 2026
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
August 20, 2026
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
August 4, 2026
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
August 3, 2026
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
July 29, 2026
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
July 21, 2026
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
May 30, 2026
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
May 26, 2026
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
May 15, 2026
1
2
Next Page
→